conventional therapy. 1 This syndrome characteristically involves angina-type pain usually in the context of epicardial CAD with or without demonstrable ischaemia. Given the heterogeneity in patients complaining of chronic chest pain, appropriate stratification of patients with regard to their risk of RA helps to direct healthcare resources tailored to individual patients' needs (see Figure 1) .
A convincing clinical history of angina, together with circumstantial evidence supporting a diagnosis, should raise clinical suspicion. The coronary anatomy in these patients is highly variable with many having had prior revascularisation (72.4 % by some estimates), and myocardial ischaemia is often difficult to detect using conventional stress imaging protocols. 10 The absence of demonstrable myocardial ischaemia in the context of epicardial CAD is not uncommon in patients referred with suspected RA and should in itself not exclude the diagnosis. Interpretation of negative functional tests must therefore consider the caveat of 1) a false negative test result or 2) the degree of ischaemia lies below the detection threshold of the imaging modality employed. Furthermore, it is important to rule out a diagnosis of non-cardiac chest pain with bystander CAD. However, when a patient's history is suggestive of angina in the absence of any other causative factor (anaemia, dyspepsia, musculoskeletal pain), the lack of demonstrable myocardial ischaemia should not absolutely preclude a diagnosis of RA.
Pharmacological Therapies
To date, no pharmacological therapy has been shown in adequatelypowered placebo-controlled randomised clinical trials (RCTs) to significantly improve symptoms and quality of life in patients with RA.
However, a significant body of evidence exists in the literature with regard to pharmacological therapy for stable angina (see Table 1 ). [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The choice of additional medication over and above first-line treatment (with either a beta-blocker or calcium channel antagonist) follows the rationale for chronic stable angina -i.e. it is considered on an individual patient basis, taking into account age, heart rate, blood pressure, the presence of diabetes mellitus or impaired renal function and tolerability. 31, 32 Follow-up 2-4 weeks after initiation of a new medication should assess its efficacy and tolerability, and dependent on whether there is any benefit, uptitration to the maximal tolerated dose should occur. If still ineffective, the medication should be stopped and an alternative considered. However, polypharmacy is a significant problem in patients with RA and rationalising medical therapy to ensure optimal benefit, adherence and tolerability is a major clinical challenge.
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Coronary Sinus Reducer
Preclinical studies have suggested that occlusion of the coronary sinus, the major venous drainage of the left heart, results in preservation of the endocardial to epicardial perfusion ratio and reduction of myocardial infarction size during coronary artery ligation. 34 These data coupled with encouraging early surgical experience motivated the development of a balloon-inflatable coronary sinus reducer device, which can be implanted via a simple trans-jugular approach (see Figure 2 ). [35] [36] [37] In normal physiology, exercise induces sympathetic vasoconstriction in the epicardial circulation, which promotes subendocardial perfusion (subendocardial:subepicardial perfusion ratio: ~1.2). 38 In the setting of epicardial CAD, this mechanism is thought to become dysfunctional. Myocardial ischaemia induces impaired regional wall motion and increased left ventricular end-diastolic pressure causes compression of the subendocardial capillaries, reducing perfusion (subendocardial:subepicardial perfusion ratio: <0.8).
Following insertion of a reducer, fibrosis occurs around the waist of the hourglass-shaped stent over a period of ~6 weeks, gradually increasing coronary sinus pressure and venous backflow. This results in dilation of venules and capillary recruitment with a reduction of resistance to subendocardial flow, which promotes recruitment of collateral flow from the subepicardium into the ischaemic subendocardium. It has also been suggested that this approach may encourage neovascularisation. has recently demonstrated significant improvements in angina symptoms and quality of life scores. 39 In the treatment group, 35 % of patients had a reduction of ≥2 CCS classes compared to 15 % in the control group (p=0.020). Quality of life, as measured by the Seattle Angina Questionnaire, improved by 17.6 (treatment) versus 7.6 points (control; p=0.030). No major adverse effects were associated with this intervention. 37, [39] [40] [41] However, it is only suitable for patients with leftsided coronary ischaemia. Consideration whether further intervention of the coronary sinus (e.g. cardiac resynchronisation therapy) may be indicated in the near future should be made, although notably, the waist of the reducer device can be dilated to allow such procedures. 42 Further results of ongoing studies to evaluate this device are eagerly awaited. 43, 44 Cell Therapy 
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progenitor cells in patients with RA. [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] After delivery, cellular products poorly engraft and are thought to improve ischaemia by promoting neovascularisation through paracrine effects although the precise mechanisms have not been fully elucidated. [55] [56] [57] Fischer et al. performed a meta-analysis demonstrating that in patients with ischaemic heart disease unsuitable for revascularisation, BMCs significantly improve Canadian Cardiovascular Society 59 Safety has been shown to be good. 59, 60 While these results are certainly encouraging, such analyses collate data from small clinical trials (phase I-II) and future work should focus on adequately powered, blinded trials with use of a sham control procedure for comparison. 61 A number of unresolved issues remain; namely the optimal cell type, preparation, dose and method of delivery. In addition, the effects of cell therapy may be shortlived and recent data from Mann et al. suggest a need for repeated administrations to maintain efficacy. 62, 63 These issues must be resolved before cellular therapy can enter routine clinical practice. 
External Enhanced Counterpulsation
Alternative non-invasive therapies have been investigated for patients with angina pectoris, including external enhanced counterpulsation (EECP). This involves a series of 1-2 hour sessions over several weeks (35 hours total), during which external compressive cuffs are placed on the calves, lower and upper thighs that are sequentially inflated from distal to proximal, synchronised to early diastole, and deflated at the onset of systole. 5, 64 This counterpulsation effect, similar to that of an intra-aortic balloon pump, promotes retrograde aortic flow with concomitant increase in diastolic pressure, increased coronary perfusion, venous return and cardiac output. Rapid deflation of the cuffs reduces systemic vascular resistance and cardiac workload. 64 Furthermore, EECP has been associated with improvement in invasive haemodynamic measures of collateral function; 65, 66 flow-mediated dilatation of large peripheral arteries; 67,68 endothelial function; 69 and mediators of inflammation and vasoconstriction. 70 A number of small studies have suggested potential benefit from EECP, the largest of which is the Multicenter Study of Enhanced External Counterpulsation (MUST-EECP) trial (n=139), which showed a reduction of self-reported angina episodes by ~25 % and time to development of 1 mm ST depression increased by ~15 %. 71 Importantly, quality of life was improved. A meta-analysis subsequently suggested that EECP achieved an improvement in angina by at least one CCS class in 86 % of patients with stable angina pectoris, though this analysis was not restricted to those patients with RA. 72 A more recent meta-analysis has reported similar results. 73 
Extracorporeal Shockwave Myocardial Revascularisation Therapy
An investigational non-invasive treatment, extracorporeal shockwave myocardial revascularisation (ESMR) therapy, involves delivering low-energy shockwaves to the border zones of ischaemic myocardium (~10 % of the high-energy counterpart used in the treatment of urolithiasis) in a series of sessions delivered over 4-9 weeks. 76, 77 Through inducing local vasodilatation and neovascularisation, it is thought to reduce ischaemia and improve left ventricular function. 78, 79 Two small RCTs in the literature have shown improvements in angina in patients with RA. 80, 81 More recently, a case-control study of 72 patients (43 cases) not only demonstrated safety but showed ESMR therapy to be associated with modest improvements in the stress 84 Further appropriately designed studies are needed to determine the mechanism and role of ESMR in RA.
Neuromodulation
The perception of pain from visceral nociceptive stimuli is complex and the severity of symptoms is often disproportionate to the degree of ischaemia. Various approaches to modulate nociceptive signals are used in patients with RA (see Figure 3) , of which, implantation of spinal cord stimulation (SCS) has received a Class IIb, Level of Evidence B, recommendation in recent ESC guidelines. 6, 31, 85 This minimally invasive procedure involves the placement of multipolar electrodes into the epidural space to deliver an electrical current to the dorsal columns between C7 and T1. 5, 86, 87 An implanted patientcontrolled pulse generator allows stimulation at the onset of angina, inducing paraesthesia at the location of anginal chest discomfort. 
Pragmatic Rehabilitation
Pragmatic rehabilitation is an important approach to promote patients to manage their own chest pain. Through learning cognitivebehavioural self-management techniques and challenging negative health beliefs, quality of life and psychological wellbeing can improve substantially. The Angina Plan is one such tool whereby patients' understanding of angina can be evaluated and misconceptions corrected. 94 It provides a structured approach to address maladaptive coping strategies in patients with angina and has been shown to significantly improve psychological wellbeing (anxiety and depression), symptoms (three episodes of angina fewer per week and reduced GTN use) and functional status (reduced physical limitation score and increased daily walking). Furthermore, from our experience, we have found that reassuring patients their symptoms are non-cardiac in origin has as important an impact as successful management of symptoms secondary to ischaemia. Furthermore, it is explained that the heart can 'adapt' to having angina through the process of ischaemic conditioning and collateralisation. 95, 96 The heightened perception of death is also challenged by discussing data from the OPTIMIST Registry (n=1,200) showing that 71.6 % of patients with RA have a 9-year life expectancy. 10 Additionally, patient awareness is raised about how their mental state can significantly affect their perception of symptoms.
The second component addresses important lifestyle adaptations that can significantly impact on patients' symptoms (e.g. learning how to pace oneself, setting realistic goals and deconstructing This facilitates an improvement in their quality of life whilst reducing dependency on resource-limited medical services. 98 Potential avenues to develop the mode of delivery may include the use of technology such as smartphone apps. Novel technological methods to deliver such therapies have been increasingly investigated, and their benefit has been recognised for chronic conditions, including cardiovascular disease, since they can effectively complement rehabilitation as well as improve adherence to medication. 99, 100 The efficacy of psychoeducational interventions in patients with chronic stable angina, including RA, has been investigated in a number of small studies, which have been analysed in a meta-analysis by McGillion et al. 101 Seven RCTs (total n=949) of self-management programmes were assessed, most of which studied the intervention delivered in follow-up. 101 Importantly, statistically significant improvements in quality of life (as per the Seattle Angina Questionnaire) were observed for physical limitation and disease perception. More recent data from refractory angina services in the UK have reported encouraging results. 97, 102, 103 A short psychological intervention consisting of four 2-hour sessions based on an angina programme combined with a course of cognitive behaviour therapy has been shown to significantly improve quality of life whilst reducing anxiety and depression. 97 Selfreported scores of 1) restriction from and 2) control over angina also significantly improved. Impressively, these results were maintained in the long term (3-year follow-up).
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A Dedicated Multidisciplinary Service
Almost by definition, the management of these 'no option' patients with RA is challenging. Their needs are best met via integrated care delivered by specialist multidisciplinary teams in dedicated specialist services (see Figure 4) . Such a framework enables addressing the issues of this heterogeneous patient cohort in a bespoke way, and allows the full spectrum of clinical management including investigative and novel treatments for appropriately selected patients. 33 Through such a combination approach involving selection from the spectrum of therapies mentioned above, management can be individually tailored to meet patients' needs. Although such resources are scarce, the recognition of the importance of multidisciplinary teams in this unique subset of patients will hopefully encourage further provision of services.
Conclusion
Whilst novel therapeutic approaches to managing these patients are welcome, evaluation of their efficacy through robust clinical data must be rigorously pursued. The development of clinical guidelines specific to RA should also be encouraged. Finally, further studies should investigate the effect of novel therapies on reducing healthcare utilisation and demonstrate cost-effectiveness in patients with RA. ■
